Analysis of the incidence of adverse events related to the administration of dipyrone
Abstract
Introduction:
Notwithstanding the widespread use of dipyrone, its association with adverse events has reduced its clinical use, with Agranulocytosis being the most studied adverse event, and apparently of primary clinical impact. Studies in Latin America have disputed these claims.
Objective:
To analyze the incidence and reports of adverse events associated with the use of dipyrone in a high complexity hospital.
Materials and methods:
Descriptive observational study of an incident cohort. Population: Patients receiving dipyrone during their hospital stay. Quantitative analysis of incidents and description of dipyrone-associated adverse events.
Results:
Incidence of global adverse events=0.3% (in 48,946 doses of dipyrone prescribed to 2747 patients). No cases of Agranulocytosis. A total 100% non-severe adverse events. (All were associated with toxidermia).
Conclusion:
A low incidence of dipyrone-associated adverse events is reported. Optimal reporting of institutional adverse events is controversial, and the recommendation is to measure any adverse events with a more rigorous follow-up of patients using dipyrone, and a clear and specific standardization of the guidelines for improved prescription and medical control.
References
2. Hearn L, Derry S, Moore RA. Single dose dipyrone (metamizole) for acute postoperative pain in adults (review). Cochrane Database Syst Rev 2016; 4:CD011421.
3. Derry S, Faura C, Edwards J, et al. Single dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 2014; 9:CD003227.
4. Edwards J, Meseguer F, Faura C, et al. Single dose dipyrone for acute renal colic pain. Cochrane Database Syst Rev 2002; 4: CD003867.
5. Kötter T, da Costa BR, Fässler M, et al. Metamizole-associated adverse events: a systematic review and meta-analysis. PLoS One 2015; 10:e0122918.
6. The International Agranulocytosis, Aplastic Anemia StudyRisks of agranulocytosis and aplastic anemia. A first report of their relation to drug use with special reference to analgesics. JAMA 1986; 256:1749-1757.
7. Hedenmalm K, Spigset O. Agranulocytosis and other blood dyscrasias associated with dipyrone (metamizole). Eur J Clin Pharmacol 2002; 58:265-274.
8. Fieler M, Eich C, Becke K, et al. Metamizole for postoperative pain therapy in 1177 children: a prospective, multicentre, observational, postauthorisation safety study. Eur J Anaesthesiol 2015; 32:839843.
9. Bigal M, Bordini C, Speciali J. Intravenous metamizol (dipyrone) in acute migraine treatment and in episodic tension-type headache-a placebo-controlled study. Cephalalgia 2001; 21:90-95.
10. Edwards J, Meseguer F, Faura C, et al. Single dose dipyrone for acute postoperative pain. Cochrane Database Syst Rev 2010; 9: CD003227.
11. Bigal ME, Bordini CA, Tepper SJ, et al. Intravenous dipyrone in the acute treatment of migraine without aura and migraine with aura: a randomized, double blind, placebo controlled study. Headache 2002; 42:862-871.
12. Hamerschlak N, Maluf E, Cavalcanti AB, et al. Incidence and risk factors for agranulocytosis in Latin American countries-the Latin Study. Eur J Clin Pharmacol 2008; 64:921-929.
13. Ibanez L, Vidal X, Ballarín E, et al. Agranulocytosis associated with dipyrone (metamizol). Eur J Clin Pharmacol 2005; 60:821-829.
14. INVIMA. Comision Revisora-Sala Especializada de Medicamentos y Productos Biológicos. Informes de Seguridad (3.6.1. Dipirona). Acta No. 03. Sesión ordinaria-presencial del 23, 24, 25 y 26 de Febrero de 2015. 2015. Paginas: 525-31, Bogotá, Colombia. Available at: https://www.invima.gov.co/rss/239-salas-especializadas/sala-especializada-de-medicamentos-y-productos-bio/ 3741-actas-2015.html. [Accessed 12 Ago 17].
15. Hamerschlak N, Maluf E, Pasquini R, et al. Incidence of aplastic anemia and agranulocytosis in Latin America: the LATIN study. Sao Paulo Med J 2005; 123:101-104.
16. Ibáñez L, Vidal X, Ballarín E, et al. Population-based drug-induced agranulocytosis. Arch Intern Med 2005; 165:869-874.
17. Maj S, Lis Y. The incidence of metamizole sodium-induced agranulocytosis in Poland. J Int Med Res 2002; 30:488-495.
18. Borja J, Galindo P, Gomez E, et al. Delayed skin reactions to metamizol. Allergy 2003; 58:84-85.
19. Stamer UM, Soehle M, Park T-W, et al. Anaphylactic reaction after intravenous dipyrone. Acute Pain 2007; 9:221-227.
20. Buitrago-González TP, Calderón-Ospina CA, Vallejos-Narváez Á. Dipirona: ¿Benefícios subestimados o riesgos sobredimensiona-dos? Revisión de la literatura. Rev Colomb Cienc Quim Farm 2014; 43:173-195.
21. Holloway K, Green T. Comitês de farmacoterapia, Guía practica. 1a ed.2003; OMS, Ginebra, Suiza:163.
Downloads
Altmetric
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
